CLDN18 and neoplasm: The pivotal phase III SPOTLIGHT and GLOW trials employed the IHC VENTANA CLDN18 (43-14A) assay kit, focusing on patients with moderate-to-strong staining (2+ or 3+) in ≥75% of tumor cells.